首页   >  
Cell Cycle/DNA Damage
  • PI3K/Akt/mTOR
  >  
ATM/ATR
  >   VE-822
VE-822 结构式

VE-822

参考资料 仅供科学研究,不可用于个人用途。
货号 :BCP07948CAS号 :1232416-25-9纯度:98%
全国免运费!免费咨询:400-099-8200 或 手机联系:13472751340
即时询价 ×

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • 基本信息与产品描述
CAS号 1232416-25-9 货号 BCP07948
中文名 VE-822
英文名 VE-822
中文别名
英文别名 VE822; VE 822; VX970; VX-970; VX 970; Berzosertib;
SMILES
化学名称
分子式 C24H25N5O3S 分子量 463.55
纯度 98% 配送 惯例下常温包邮
产品描述 VE-822, also known as VX-970 or Berzosertib, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, increased persistent DNA damage and decreased homologous recombination in irradiated cancer cells. VE-822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. VE-822 markedly prolonged growth delay of pancreatic cancer xenografts after XRT and gemcitabine-based chemoradiation without augmenting normal cell or tissue toxicity. These findings support ATR inhibition as a promising new approach to improve the therapeutic ration of radiochemotherapy for patients with PDAC.
  • 技术资料和支持
在购买和使用瀚香生物产品的过程中,您遇到的任何问题,都可以咨询我们的免费热线:400-099-8200,或者和我们的客服 。 我们竭诚解决您的一切疑惑,保证您的舒心顺畅。

相关产品推荐

查看更多 >

Tags:VE-822 供应商,VE-822 购买,VE-822 生产,VE-822 批量,VE-822 供应,VE-822 订购,VE-822 采购

2853530910